AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12151889 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 40
Study 12151889 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (Hohmann operation)
Number of subjects: 40
Study 9950667 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoflux
Number of subjects: 0
Study 9950667 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 9950667 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 0
Study 9950667 — intervention group
Group type: COMPARATOR
Intervention: Hirudin
Number of subjects: 0
Study 9950667 — intervention group
Group type: COMPARATOR
Intervention: Dermatan sulfate
Number of subjects: 0
Study 7488768 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow (PULS-group)
Number of subjects: 20
Study 7488768 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile flow (CON-group)
Number of subjects: 20
Study 2107518 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus b conjugate vaccine (meningococcal protein conjugate), PedvaxHIB (PRP‐OMPC)
Number of subjects: 0
Study 373391 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dosage of clomipramine (150 mg at night for 10 days)
Number of subjects: 16
Study 373391 — intervention group
Group type: COMPARATOR
Intervention: Divided daily dosage of clomipramine (150 mg three times daily for 10 days)
Number of subjects: 16
Study 373391 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dosage of clomipramine
Number of subjects: 16
Study 373391 — intervention group
Group type: COMPARATOR
Intervention: Divided daily dosage of clomipramine
Number of subjects: 16
Study 30832230 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of Glutamine (Gln) for 14 days
Number of subjects: 39
Study 30832230 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (Gln) in Wistar rats on a high-fat diet (HFD)
Number of subjects: 39
Study 30899946 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP followed by topical use of rhubarb extract
Number of subjects: 50
Study 30899946 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planning (SRP)
Number of subjects: 50
Study 26859388 — intervention group
Group type: EXPERIMENTAL
Intervention: DIALOG+ intervention
Number of subjects: 0
Study 24965335 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 609
Study 24965335 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 609
Study 22007679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-Curing Technique (DC): Excite DSC and RelyX ARC, light-cured for 60 s
Number of subjects: 34
Study 22007679 — intervention group
Group type: COMPARATOR
Intervention: Light-Curing Self-Adhering Technique (LCSA): Vertise Flow, light-cured for 60 s
Number of subjects: 34
Study 20354445 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EX)
Number of subjects: 21
Study 20354445 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 21
Study 17623113 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD) alone
Number of subjects: 10
Study 17623113 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap debridement with enamel matrix derivatives (EMD)
Number of subjects: 10
Study 16275936 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) with autologous stem-cell transplantation (melphalan 200 mg/m2 IV or melphalan 140 mg/m2 IV plus busulfan 16 mg/kg orally)
Number of subjects: 190
Study 16275936 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (CCT; monthly courses of vincristine, melphalan, cyclophosphamide, and prednisone)
Number of subjects: 190
Study 12561063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of Tc‐99m tin colloid (0.4‐5 microm)
Number of subjects: 116
Study 12561063 — intervention group
Group type: COMPARATOR
Intervention: Subdermal injection of radiocolloids
Number of subjects: 116
Study 10418541 — intervention group
Group type: EXPERIMENTAL
Intervention: Twenty‐minute educational videotape on advantages and disadvantages of prostate‐specific antigen (PSA) screening for prostate cancer
Number of subjects: 160
Study 10418541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study 7538712 — intervention group
Group type: EXPERIMENTAL
Intervention: TUIP (transurethral incision of the prostate)
Number of subjects: 120
Study 7538712 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP (transurethral resection of the prostate)
Number of subjects: 120
Study 2268864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 to 40 mg daily for six months)
Number of subjects: 15
Study 6104614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (once daily for 12 weeks)
Number of subjects: 75
Study 6104614 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (four times per day for 12 weeks)
Number of subjects: 75
Study 31734589 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) at a dose of 20Gy in 1 fraction to each metastasis
Number of subjects: 15
Study 31229502 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Learning Environment (VLE)
Number of subjects: 40
Study 31229502 — intervention group
Group type: COMPARATOR
Intervention: Didactic teaching
Number of subjects: 40
Study 30192018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecopipam (50 mg/day for weight <34 kg, 100 mg/day for weight >34 kg)
Number of subjects: 40
Study 30192018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27434094 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone alone (90 mg once daily)
Number of subjects: 220
Study 27434094 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol addition (2 mg twice daily)
Number of subjects: 220
Study 25112096 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric-thermal Bian-stone therapy (group A)
Number of subjects: 41
Study 25112096 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion box therapy (group B)
Number of subjects: 41
Study 22804796 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise programme including pelvic floor muscle training (PFMT), conducted between 20 and 36 weeks of gestation, with one weekly group session led by physiotherapists and home exercises encouraged at least twice a week.
Number of subjects: 855
Study 22804796 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise programme including pelvic floor muscle training (PFMT).
Number of subjects: 855
Study 22804796 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (control group).
Number of subjects: 855
Study 19464164 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 327
Study 19464164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB)
Number of subjects: 327
Study 19464164 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) in triple-negative tumours
Number of subjects: 327
Study 19464164 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) in HER2-positive tumours
Number of subjects: 327
Study 17594986 — intervention group
Group type: EXPERIMENTAL
Intervention: I'm-Yunity (Coriolus versicolor) 1200 mg, three times daily for 14 days
Number of subjects: 12
Study 15446758 — intervention group
Group type: COMPARATOR
Intervention: NK-1 receptor antagonists (specific drug not mentioned), administered before chemotherapy and continued twice daily for five days.
Number of subjects: 0
Study 15446758 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy with granisetron and dexamethasone.
Number of subjects: 0
Study 15446758 — intervention group
Group type: EXPERIMENTAL
Intervention: NK-1 receptor antagonists (specific drug not mentioned), cost of Can$6.60 per dose.
Number of subjects: 0
Study 15446758 — intervention group
Group type: EXPERIMENTAL
Intervention: NK-1 receptor antagonists (specific drug not mentioned), total cost for five days of therapy.
Number of subjects: 0
Study 11174482 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography
Number of subjects: 1926
Study 9628295 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise (1 hour, 4 times per week, for 2 months at 75% of physical working capacity)
Number of subjects: 18
Study 9628295 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 boys who did not participate in any specific program)
Number of subjects: 18
Study 7851238 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific, intensive diabetes education program (2-hour nutrition education session)
Number of subjects: 152
Study 7851238 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education session)
Number of subjects: 152
Study 3290585 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 62
Study 3290585 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 62
Study 3290585 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 62
Study 29273485 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCon GH (0.04, 0.08, 0.16, or 0.24mg GH/kg/wk)
Number of subjects: 44
Study 29273485 — intervention group
Group type: COMPARATOR
Intervention: Omnitrope (0.08 or 0.16mg GH/kg/wk divided into 7 equal daily doses)
Number of subjects: 44
Study 29273485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 27901255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional guidance
Number of subjects: 53
Study 25211291 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized manual physiotherapy plus individualized exercises
Number of subjects: 90
Study 25211291 — intervention group
Group type: COMPARATOR
Intervention: Individualized exercises only (Control)
Number of subjects: 90
Study 23017200 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 1497
Study 23017200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1497
Study 20668673 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide, with or without perindopril
Number of subjects: 0
Study 20668673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18827177 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/kg bevacizumab (Avastin) administered every 2 weeks
Number of subjects: 0
Study 18827177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15940776 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP 90 mg once daily
Number of subjects: 161
Study 15940776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 12810413 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan (experimental phase)
Number of subjects: 20
Study 12810413 — intervention group
Group type: COMPARATOR
Intervention: Control (usual food intake)
Number of subjects: 20
Study 10319666 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor walking exercise program (40-60% target heart-rate, 50-60 min, 3 times per week for 8 weeks)
Number of subjects: 27
Study 10319666 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor walking exercise program
Number of subjects: 27
Study 10319666 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 8752790 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 520
Study 8752790 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 520
Study 8752790 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ischemic episodes response (100% responders)
Number of subjects: 520
Study 8752790 — intervention group
Group type: COMPARATOR
Intervention: Transient ischemic episodes response (non-100% responders)
Number of subjects: 520
Study 8752790 — intervention group
Group type: COMPARATOR
Intervention: Two or more ischemic episodes
Number of subjects: 520
Study 8752790 — intervention group
Group type: COMPARATOR
Intervention: More than six episodes
Number of subjects: 520
Study 8317411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg (three premeal doses)
Number of subjects: 15
Study 8317411 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (single morning dose)
Number of subjects: 15
Study 8317411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3594278 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial prevention program participation
Number of subjects: 30
Study 3594278 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteaching of the prevention program
Number of subjects: 30
Study 3594278 — intervention group
Group type: COMPARATOR
Intervention: Previous control group participation
Number of subjects: 30
Study 29526341 — intervention group
Group type: EXPERIMENTAL
Intervention: Therabite® jaw motion rehabilitation system
Number of subjects: 71
Study 29526341 — intervention group
Group type: COMPARATOR
Intervention: Wooden spatulas
Number of subjects: 71
Study 28806907 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (6 sessions per week for 4 weeks, total of 24 sessions)
Number of subjects: 40
Study 28806907 — intervention group
Group type: COMPARATOR
Intervention: Estazolam (1-2 mg/day taken 30 minutes before sleep for 4 weeks)
Number of subjects: 40
Study 26399940 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% of maximum voluntary contraction (MVC)
Number of subjects: 12
Study 26399940 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of maximum voluntary contraction (MVC)
Number of subjects: 12
Study 26399940 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% of maximum voluntary contraction (MVC)
Number of subjects: 12
Study 26399940 — intervention group
Group type: COMPARATOR
Intervention: Control measurement of maximum 3s position in the joint at 90°
Number of subjects: 12
Study 23557728 — intervention group
Group type: EXPERIMENTAL
Intervention: McConnell taping
Number of subjects: 20
Study 23557728 — intervention group
Group type: EXPERIMENTAL
Intervention: Spider(®) taping
Number of subjects: 20
Study 21672316 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml 6% hydroxyethyl starch 130/0.4 (HES)
Number of subjects: 50
Study 21672316 — intervention group
Group type: COMPARATOR
Intervention: 500 ml 4% succinylated gelatine (GEL)
Number of subjects: 50
Study 18384489 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability training of the lumbo‐pelvo‐hip complex (LPHC) for 4 weeks
Number of subjects: 30
Study 18384489 — intervention group
Group type: COMPARATOR
Intervention: Control group remained unaffected
Number of subjects: 30
Study 16513858 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release methylphenidate (40 mg)
Number of subjects: 12
Study 16513858 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release methylphenidate (90 mg)
Number of subjects: 12
Study 12753943 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE+MPA (0.625 mg conjugated equine estrogens combined with 2.5 mg medroxyprogesterone acetate)
Number of subjects: 105
Study 12753943 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE+MPA
Number of subjects: 105
Study 12753943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 12753943 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 105
Study 10946805 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-supplemented very-low-protein diet (VLPD)
Number of subjects: 0
Study 10946805 — intervention group
Group type: COMPARATOR
Intervention: Dialysis
Number of subjects: 0
Study 8572841 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP Step I diet
Number of subjects: 89
Study 8572841 — intervention group
Group type: COMPARATOR
Intervention: NCEP Step I diet with quick-service meals (NCEP-QS)
Number of subjects: 89
Study 1741552 — intervention group
Group type: EXPERIMENTAL
Intervention: Human surfactant containing SP‐A
Number of subjects: 61
Study 1741552 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 61
Study 6963097 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal administration during maintenance therapy with digoxin
Number of subjects: 0
Study 6963097 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal administration during maintenance therapy with digitoxin
Number of subjects: 0
Study 6963097 — intervention group
Group type: COMPARATOR
Intervention: Fibre administration
Number of subjects: 0
Study 30507562 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐min manual protocol of plantar stimulation on the right foot (Experimental Group, EG)
Number of subjects: 98
Study 30507562 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 98
Study 28753067 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTO 6785
Number of subjects: 187
Study 28753067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 26474237 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rifaximin (400mg every 12 hours for 2 weeks)
Number of subjects: 43
Study 26474237 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifaximin (600mg every 12 hours for 2 weeks)
Number of subjects: 43
Study 26474237 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rifaximin treatment)
Number of subjects: 43
Study 23282190 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation
Number of subjects: 925
Study 20938352 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (anodal DC of the DLPFC)
Number of subjects: 82
Study 20938352 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (cathodal DC of the DLPFC)
Number of subjects: 82
Study 20938352 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (intermittent anodal DC of the DLPFC)
Number of subjects: 82
Study 20938352 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (AC on the zygomatic process)
Number of subjects: 82
Study 20938352 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 82
Study 19603229 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate mesh
Number of subjects: 73
Study 19603229 — intervention group
Group type: COMPARATOR
Intervention: Polyvidone iodine mesh
Number of subjects: 73
Study 17100681 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-recall group
Number of subjects: 55
Study 17100681 — intervention group
Group type: COMPARATOR
Intervention: ICD-control group
Number of subjects: 55
Study 17100681 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA II group
Number of subjects: 55
Study 17100681 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic shock experience
Number of subjects: 55
Study 14710204 — intervention group
Group type: EXPERIMENTAL
Intervention: Scientific and psychosocial information pack (Group 1)
Number of subjects: 163
Study 14710204 — intervention group
Group type: EXPERIMENTAL
Intervention: Scientific information pack only (Group 2)
Number of subjects: 163
Study 14710204 — intervention group
Group type: COMPARATOR
Intervention: Standard care control (Group 3)
Number of subjects: 163
Study 11323358 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine with 0.0002% fentanyl
Number of subjects: 98
Study 11323358 — intervention group
Group type: COMPARATOR
Intervention: 0.1% ropivacaine with 0.0002% fentanyl
Number of subjects: 98
Study 9218083 — intervention group
Group type: EXPERIMENTAL
Intervention: Zamifenacin 40 mg
Number of subjects: 36
Study 9218083 — intervention group
Group type: EXPERIMENTAL
Intervention: Zamifenacin 10 mg
Number of subjects: 36
Study 9218083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7752825 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mcg of selenium (as sodium selenite) followed by 100 mg coenzyme Q10 (Bio‐Quinone) and 100 mcg selenium (Bio‐Selenium in the form of 1‐seleno‐methionine) for one year
Number of subjects: 61
Study 7752825 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo preparations
Number of subjects: 61
Study 3054778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 80 to 100 mg/kg/day for 4 days
Number of subjects: 20
Study 3054778 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 20
Study 31811480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystine/Theanine
Number of subjects: 100
Study 31811480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31473324 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted hypothermia (33°C)
Number of subjects: 1900
Study 31473324 — intervention group
Group type: COMPARATOR
Intervention: Normothermia and early treatment of fever (≥37.8°C)
Number of subjects: 1900
Study 28343218 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (50 mg/kg)
Number of subjects: 28
Study 28343218 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 28
Study 26604728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud Bath Therapy (MBT), n=22
Number of subjects: 42
Study 26604728 — intervention group
Group type: COMPARATOR
Intervention: Leisure Thermal Activity (LTA), n=19
Number of subjects: 42
Study 23306009 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative CT densitometry (qCTD)
Number of subjects: 81
Study 23306009 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline volume (BV)
Number of subjects: 81
Study 23306009 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-to-scan (TTS)
Number of subjects: 81
Study 23306009 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model of qCTD, BV, and TTS
Number of subjects: 81
Study 23306009 — intervention group
Group type: EXPERIMENTAL
Intervention: qCTD
Number of subjects: 81
Study 21699876 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-efficacy regarding the ability to exert control over pain
Number of subjects: 79
Study 21699876 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated pain intensity
Number of subjects: 79
Study 18788410 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin stimulating agents (ESAs) treatment targeting higher hemoglobin levels (near normal level)
Number of subjects: 0